Genetic basis of thrombosis

Clinical Chemistry and Laboratory Medicine

Volumn 48, Issue SUPPL. 1, 2010, Pages

  Bafunno, Valeria ^a   Margaglionex, Maurizio ^a,b  

^a UNIVERSITY OF FOGGIA   (Italy)

^b CASA SOLLIEVO DELLA SOFFERENZA HOSPITAL   (Italy)

Author keywords

case control studies; family studies; genetic risks factors; venous thrombosis

Indexed keywords

ANTITHROMBIN; BLOOD CLOTTING FACTOR 13; BLOOD CLOTTING FACTOR 5; BLOOD CLOTTING FACTOR 9; ENDOTHELIAL PROTEIN C RECEPTOR; FIBRINOGEN; PADGEM PROTEIN; PROTEIN C; PROTEIN S; PROTHROMBIN; THROMBIN ACTIVATABLE FIBRINOLYSIS INHIBITOR; THROMBOMODULIN; THROMBOPLASTIN;

ANTITHROMBIN DEFICIENCY; BLOOD GROUP O; FAMILY HISTORY; GENETIC ASSOCIATION; GENETIC RISK; GENETIC VARIABILITY; HEREDITY; HUMAN; HYPERHOMOCYSTEINEMIA; LOSS OF FUNCTION MUTATION; PRIORITY JOURNAL; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM; VEIN THROMBOSIS;

BLOOD COAGULATION FACTORS; GENETIC PREDISPOSITION TO DISEASE; GENOME-WIDE ASSOCIATION STUDY; HUMANS; RISK FACTORS; THROMBOSIS;

EID: 79251608071     PISSN: 14346621     EISSN: 14374331     Source Type: Journal    
DOI: 10.1515/CCLM.2010.361     Document Type: Review

References (101)

1. Macfarlane RG. Haemostasis: Introduction. Br Med Bull 1977;33:183-5.
2. Reistma PH, Rosendaal FR. Past and future of genetic research in thrombosis. J Thromb Haemost 2007;5:264-9.
3. Naess IA, Christiansen SC, Romundstad P, Cannegieter SC, Rosendaal FR, Hammerstrøm J. Incidence and mortality of venous thrombosis: A population-based study. J Thromb Haemost 2007;5:692-9.
4. Kyrle PA, Minar E, Bialonczyk C, Hirschl M, Weltermann A, Eichinger S. The risk of recurrent venous thromboembolism in men and women. N Engl J Med 2004;350:2558-63.
5. Bronić A. Thromboembolic diseases as biological and clinical syndrome - role of the Mediterranean League against Thromboembolic Diseases. Biochem Med 2010;20:9-12.
6. Souto JC, Almasy L, Borrell M, Blanco-Vaca F, Mateo J, Soria JM, et al. Genetic susceptibility to thrombosis and its relationship to physiological risk factors: The GAIT study. Am J Hum Genet 2000;67:1452-9.
7. Briggs J. Recurrent phlebitis of obscure origin Bull. John Hopkins Hosp 1905;16:228-33.
8. Rosendaal FR, Reitsma PH. Genetics of venous thrombosis. J Thromb Haemost 2009;7:301-4.
9. Bezemer ID, van der Meer FJ, Eikenboom JC, Rosendaal FR, Doggen CJ. The value of family history as a risk indicator for venous thrombosis. Arch Intern Med 2009;169:610-5.
10. Tait RC, Walker ID, Perry DJ, Islam SI, Daly ME, McCall F, et al. Prevalence of antithrombin deficiency in the healthy population. Br J Haematol 1994;87:106-12.
11. van Boven HH, Lane DA. Antithrombin and its inherited deficiency states. Semin Hematol 1997;34:188-204.
12. Lane DA, Mannucci PM, Bauer KA, Bertina RM, Bochkov NP, Boulyjenkov V, et al. Inherited thrombophilia: Part I. Thromb Haemost 1996;76:651-62.
13. Lane DA, Bayston T, Olds RJ, Fitches AC, Cooper DN, Millar DS, et al. Antithrombin mutation database: 2nd (1997) update. For the Plasma Coagulation Inhibitors Subcommittee of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis. Thromb Haemost 1997;77:197-211.
14. Olds RJ, Lane DA, Chowdhury V, De Stefano V, Leone G, Thein SL. Complete nucleotide sequence of the antithrombin gene: Evidence for homologous recombination causing thrombophilia. Biochemistry 1993;32:4216-24.
15. van Boven HH, Olds RJ, Thein SL, Reistma PH, Lane DA, Briet E, et al. Hereditary antithrombin deficiency: Heterogeneity of the molecular basis and mortality in Dutch families. Blood 1994;84:4209-13.
16. Patnaik MM, Moll S. Inherited antithrombin deficiency: A review. Haemophilia 2008;14:1229-39.
17. Demers C, Ginsberg JS, Hirsh J, Henderson P, Blajchman MA. Thrombosis in antithrombin III-deficient persons: Report of a large kindred and literature review. Ann Intern Med 1992;116:754-6.
18. Bucciarelli P, Rosendaal FR, Tripodi A, Mannucci PM, De Stefano V, Palareti G, et al. Risk of venous thromboembolism and clinical manifestations in carriers of antithrombin, protein C, protein S deficiency, or activated protein C resistance. A multicenter collaborative family study. Arterioscler Thromb Vasc Biol 1999;19:1026-33.
19. Broekmans AW, Veltkamp JJ, Bertina RM. Congenital protein C deficiency and venous thromboembolism: A study of three Dutch families. N Engl J Med 1983;309:340-4.
20. Schwarz HP, Fischer M, Hopmeier P, Batard MA, Griffin JH. Plasma protein S deficiency in familial thrombotic disease. Blood 1984;64:1297-300.
21. Allaart CF, Poort SR, Rosendaal FR, Reitsma PH, Bertina RM, Briet E. Increased risk of venous thrombosis in carriers of hereditary protein C deficiency defect. Lancet 1993;341: 134-8.
22. Reitsma PH. Protein C deficiency: From gene defects to disease. Thromb Haemost 1997;8:344-50.
23. Millar DS, Johansen B, Berntorp E, Minford A, Bolton-Maggs P, Wensley R, et al. Molecular genetic analysis of severe protein C deficiency. Hum Genet 2000;106:646-53.
24. Reitsma PH, Bernardi F, Doig RG, Gandrille S, Greengard JS, Ireland H, et al. Protein C deficiency: A database of mutations, 1995 update. On behalf of the Subcommittee on Plasma Coagulation Inhibitors of the Scientific and Standardization Committee of the ISTH. Thromb Haemost 1995;73:876-89.
25. Makris M, Leach M, Beauchamp NJ, Daly ME, Cooper PC, Hampton KK, et al. Genetic analysis, phenotypic diagnosis, and risk of venous thrombosis in families with inherited deficiencies of protein S. Blood 2000;95:1935-41.
26. García de Frutos P, Fuentes-Prior P, Hurtado B, Sala N. Molecular basis of protein S deficiency. Thromb Haemost 2007;98:543-56.
27. Pintao MC, Garcia AA, Borgel D, Alhenc-Gelas M, Spek CA, de Visser MC, et al. Gross deletions/duplications in PROS1 are relatively common in point mutation-negative hereditary protein S deficiency. Hum Genet 2009;126:449-56.
28. Koster T, Rosendaal FR, Briët E, van der Meer FJ, Colly LP, Trienekens PH, et al. Protein C deficiency in a controlled series of unselected outpatients: An infrequent but clear risk factor for venous thrombosis (Leiden Thrombophilia Study). Blood 1995;85:2756-61.
29. Vossen CY, Conard J, Fontcuberta J, Makris M, van der Meer FJ, Pabinger I, et al. Familial thrombophilia and lifetime risk of venous thrombosis. J Thromb Haemost 2004;2:1526-32.
30. Heijboer H, Brandjes DP, Büller HR, Sturk A, Ten Cate JW. Deficiencies of coagulation - inhibiting and fibrinolytic proteins in outpatients with deep-vein thrombosis. N Engl J Med 1990;323:1512-6.
31. Zöller B, Berntsdotter A, Garcia de Frutos P, Dahlback B. Resistance to activated protein C as an additional genetic risk factor in hereditary deficiency of protein S. Blood 1995; 85:3518-23.
32. Hasstedt SJ, Bovill EG, Callas PW, Long GL. An unknown genetic defect increases venous thrombosis risk, through interaction with protein C deficiency. Am J Hum Genet 1998; 63:569-76.
33. Mahmoodi BK, Brouwer JL, Veeger NJ van der Meer J. Hereditary deficiency of protein C or protein S confers increased risk of arterial thromboembolic events at a young age: Results from a large family cohort study. Circulation 2008;118:1659-67.
34. Dahlbäck B, Carlsson M, Svensson P. Familial thrombophilia due to a previously unrecognized mechanism characterized by poor anticoagulant response to activated protein C: Prediction of a cofactor to activated protein C. Proc Natl Acad Sci USA 1993;90:1004-8.
35. Bertina RM, Koeleman RP, Koster T, Rosendaal FR, Dirven RJ, de Ronde H, et al. Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature 1994;369:64-7.
36. Martinelli I, Mannucci PM, De Stefano V, Taioli E, Rossi V, Crosti F, et al. Different risks of thrombosis in four coagulation defects associated with inherited thrombophilia: A study of 150 families. Blood 1998;92:2353-8.
37. Rosendaal FR, Koster T, Vandenbroucke JP, Reitsma PH. High risk of thrombosis in patients homozygous for factor V Leiden (activated protein C resistance). Blood 1995;85: 1505-8.
38. Bauduer F, Lacombe D. Factor V Leiden, prothrombin 20210A, methylenetetrahydrofolate reductase 677T, and population genetics. Mol Genet Metab 2005;86:91-9.
39. Rees DC, Cox M, Clegg JB. World distribution of factor V Leiden. Lancet 1995;346:1133-4.
40. Griffin JH, Xu X, Pabinger I, Samama M, Conard J, Brenner B, et al. A single genetic origin for a common Caucasian risk factor for venous thrombosis. Blood 1997;89:397-402.
41. Lindqvist PG, Svensson PJ, Dahlback B, Marsal K. Factor V Q506 mutation (activated protein C resistance) associated with reduced intrapartum blood loss - a possible evolutionary selection mechanism. Thromb Haemost 1998;79:69-73.
42. Alfirevic Z, Simundic AM, Nikolac N, Sobocan N, Alfirevic I, Stefanovic M, et al. Frequency of factor II G20210A, factor V Leiden, MTHFR C677T and PAI-1 5G/4G polymorphism in patients with venous thromboembolism: Croatian case-control study. Biochem Med 2010;20:229-35.
43. De Stefano V, Martinelli I, Mannucci PM, Paciaroni K, Chiusolo P, Casorelli I, et al. The risk of recurrent deep venous thrombosis among heterozygous carriers of both factor V Leiden and the G20210 A prothrombin mutation. N Engl J Med 2000;341:801-6.
44. Margaglione M, D'Andrea G, Colaizzo D, Cappucci G, del Popolo A, Brancaccio V, et al. Coexistence of factor V Leiden and factor II A20210 mutation and recurrent venous thromboembolism. Thromb Haemost 1999;82:1583-7.
45. Simioni P, Prandoni P, Lensing AW, Scudeller A, Sardella C, Prins MH, et al. The risk of recurrent venous thromboembolism in patients with an Arg506 Gln mutation in the gene for factor V. N Engl J Med 1997;336:399-403.
46. Bernardi F, Faioni EM, Castoldi E, Lunghi B, Castaman G, Sacchi E, et al. A factor V genetic component differing from factor V R506Q contributes to the activated protein C resistance phenotype. Blood 1997;90:1552-7.
47. Williamsson D, Brown K, Luddington R, Baglin C, Baglin T. A new mutation (Arg306Thr) associated with resistance to activated protein C. Blood 1998;91:1140-4.
48. Chan WP, Lee CK, Kwong YL, Lam CK, Liang R. A novel mutation of Arg306 of factor V gene in Hong Kong Chinese. Blood 1998;91:1135-9.
49. Poort SW, Rosendaal FR, Reitsma PH, Bertina RM. A common genetic variation in the 3'-untranslated region of the prothrombin gene is associated with elevated plasma prothrombin levels and an increase in venous thrombosis. Blood 1996; 88:3698-703.
50. Rosendaal FR, Doggen CJ, Zivelin A, Arruda VR, Aiach M, Siscovick DS, et al. Geographic distribution of the 20210 G to A prothrombin variant. Thromb Haemost 1998;79:706-8.
51. Lijfering WM, Middeldorp S, Veeger JG, Hamulyak K, Prins MH, Buller HR, et al. Risk of recurrent venous thrombosis in homozygous carriers and double heterozygous carriers of factor V Leiden and prothrombin G20210A. Circulation 2010; 121:1706-12.
52. Simioni P, Prandoni P, Burlina A, Tormene D, Sardella C, Ferrari V, et al. Hyperhomocysteinemia and deep vein thrombosis: A case control study. Thromb Haemost 1996;76:883-6.
53. Mudd SH, Skovby F, Levy HL, Pettigrew KD, Wilcken B, Pyeritz RE, et al. The natural history of homocystinuria due to cystathionine beta-synthase deficiency. Am J Hum Genet 1985;37:1-31.
54. Goyette P, Frosst P, Rosenblatt DS, Rozen R. Seven novel mutations in the methylenetetrahydrofolate reductase gene and genotype/phenotype correlations in severe methylenetetrahydrofolate reductase deficiency. Am J Hum Genet 1995;56: 1052-9.
55. Sibani S, Christensen B, O'Ferrall E, Saadi I, Hiou-Tim F, Rosenblatt DS, et al. Characterization of six novel mutations in the methylenetetrahydrofolate reductase (MTHFR) gene in patients with homocystinuria. Hum Mutat 2000;15:280-7.
56. Kraus JP, Janosík M, Kozich V, Mandell R, Shih V, Sperandeo MP, et al. Cystathionine beta-synthase mutations in homocystinuria. Hum Mutat 1999;13:362-75.
57. Pereira AC, Schettert IT, Morandini Filho AA, Guerra-Shinohara EM, Krieger JE. Methylenetetrahydrofolate reductase (MTHFR) C677T gene variant modulates the homocysteine folate correlation in a mild folate-deficient population. Clin Chim Acta 2004;340:99-105.
58. Tsai AW, Cushman M, Tsai MY, Heckbert SR, Rosamond WD, Aleksic N, et al. Serum homocysteine, thermolabile variant of methylenetetrahydrofolate reductase (MTHFR) and venous thromboembolism: Longitudinal Investigation of thromboembolism Etiology (LITE). Am J Hematol 2003;72: 192-200.
59. Bezemer ID, Doggen CJ, Vos HL, Rosendaal FR. No association between the common MTHFR 677C)T polymorphism and venous thrombosis: Results from MEGA study. Arch Intern Med 2007;167:497-501.
60. Pepe G, Camacho Vanegas O, Giusti B, Brunelli T, Marcucci R, Attanasio M, et al. Heterogeneity in world distribution of the thermolabile C677T mutation in 5,10-methylenetetrahydrofolate reductase. Am J Hum Genet 1998;63:917-20.
61. Esfahani ST, Cogger EA, Caudill MA. Heterogeneity in the prevalence of methylenetetrahydrofolate reductase gene polymorphisms in women of different ethnic groups. J Am Diet Assoc 2003;103:200-7.
62. Weisberg I, Tran P, Christensen B, Sibani S, Rozen R. A second genetic polymorphism in methylenetetrahydrofolate reductase (MTHFR) associated with decreased enzyme activity. Mol Genet Metab 1999;68:511-2.
63. Botto LD, Yang Q. 5,10-Methylenetetrahydrofolate reductase gene variants and congenital anomalies: A HuGE review. Am J Epidemiol 2000;151:862-77.
64. Franco RF, Elion J, Lavinha J, Krishnamoorthy R, Tavella MH, Zago MA. Heterogeneous ethnic distribution of the 844ins68 in the cystathionine b-synthase gene. Hum Hered 1998;48:338-42.
65. Franco R, Maffei F, Lourenço D, Piccinato C, Morelli V, Thomazini I, et al. The frequency of 844ins68 mutation in the cystathionine b-synthase gene is not increased in patients with venous thrombosis. Haematologica 1998;83:1006-8.
66. de Franchis R, Fermo I, Mazzola G, Sebastio G, Di Minno G, Coppola A, et al. Contribution of the cystathionine betasynthase gene (844ins68) polymorphism to the risk of earlyonset venous and arterial occlusive disease and fasting hyperhomocysteinemia. Thromb Haemost 2000;84:576-82.
67. Jick H, Slone D, Westerholm B, Inman WH, Vessey MP, Shapiro S, et al. Venous thromboembolic disease and ABO blood type. A cooperative study. Lancet 1969;1:539-42.
68. Morelli VM, De Visser MC, Vos HL, Bertina RM, Rosendaal FR. ABO blood group genotypes and the risk of venous thrombosis: Effect of factor V Leiden. J Thromb Haemost 2005;3:183-5.
69. Minano A, Ordónez A, Espana F, González-Porras JR, Lecumberri R, Fontcuberta J, et al. ABO blood group and risk of venous or arterial thrombosis in carriers of factor V Leiden or prothrombin G20210A polymorphisms. Haematologica 2008;93:729-34.
70. Mosesson MW. Dysfibrinogenemia and thrombosis. Semin Thromb Hemost 1999;25:311-9.
71. de Willige SU, de Visser MC, Houwing-Duistermaat JJ, Rosendaal FR, Vos HL, Bertina RM. Genetic variation in the fibrinogen gamma gene increases the risk for deep venous thrombosis by reducing plasma fibrinogen γ' levels. Blood 2005;106:4176-83.
72. de Willige SU, Pyle ME, Vos HL, de Visser MC, Lally C, Dowling NF, et al. Fibrinogen gamma gene 3'-end polymorphisms and risk of venous thromboembolism in the African- American and Caucasian population. Thromb Haemost 2009; 101:1078-84.
73. Simsek I, de Mazancourt P, Horellou MH, Erdem H, Pay S, Dinc A, et al. Afibrinogenemia resulting from homozygous nonsense mutation in A alpha chain gene associated with multiple thrombotic episodes. Blood Coagul Fibrinolysis 2008; 19:247-53.
74. Muszbek L, Bagoly Z, Bereczky Z, Katona E. The involvement of blood coagulation factor XIII in fibrinolysis and thrombosis. Cardiovasc Hematol Agents Med Chem 2008; 6:190-205.
75. Attié-Castro FA, Zago MA, Lavinha J, Elion J, Rodriguez- Delfin L, Guerreiro JF, et al. Ethnic heterogeneity of the factor XIII Val34Leu polymorphism. Thromb Haemost 2000;84: 601-3.
76. Catto AJ, Kohler HP, Coore J, Mansfield MW, Stickland MH, Grant PJ. Association of a common polymorphism in the factor XIII gene with venous thrombosis. Blood 1999;93:906-8.
77. Wells PS, Anderson JL, Scarvelis DK, Doucette SP, Gagnon F. Factor XIII Val34Leu variant is protective against venous thromboembolism: A HuGE review and meta-analysis. Am J Epidemiol 2006;164:101-9.
78. Vossen CY, Rosendaal RF. Protective effect of the factor XIII/ Val34Leu mutation on the risk of deep venous thrombosis is dependent on the fibrinogen level. J Thromb Haemost 2005;3:1102-3.
79. Dahm A, van Hylckama Vlieg A, Bendz B, Rosendaal F, Bertina RM, Sandset PM. Low levels of tissue factor pathway inhibitor (TFPI) increase the risk of venous thrombosis. Blood 2003;101:4387-92.
80. Miyata T, Sakata T, Kumeda K, Uchida K, Tsushima M, Fujimura H, et al. C-399T polymorphism in the promoter region of human tissue factor pathway inhibitor TFPI gene does not change the plasma TFPI antigen level and does not cause venous thrombosis. Thromb Haemost 1998;80:345-6.
81. Moatti D, Haidar B, Fumeron F, Gauci L, Boudvillain O, Seknadji P, et al. A new T-287 C polymorphism in the 5' regulatory region of the tissue factor pathway inhibitor gene. Association study of the T-287 C and C-399 T polymorphisms with coronary artery disease and plasma TFPI levels. Thromb Haemost 2000;84:244-9.
82. Amini-Nekoo A, Futers TS, Moia M, Mannucci PM, Grant PJ, Ariëns RA. Analysis of the tissue factor pathway inhibitor gene and antigen levels in relation to venous thrombosis. Br J Haematol 2000;113:537-43.
83. Kleesiek K, Schmidt M, Götting C, Brinkmann T, Prohaska W. A first mutation in the human tissue factor pathway inhibitor gene encoding wP151LxTFPI. Blood 1998;92:3976-7.
84. Kleesiek K, Schmidt M, Gotting C, Schwenz B, Lange S, Muller-Berghaus G, et al. The 536C → T transition in the human tissue factor pathway inhibitor (TFPI) gene is statistically associated with a higher risk for venous thrombosis. Thromb Haemost 1999;82:1-5. (Pubitemid 29368763)
85. Gonzalez-Conejero R, Lozano ML, Corral J, Martinez C, Vicente V. The TFPI 536C → T mutation is not associated with increased risk for venous or arterial thrombosis. Thromb Haemost 2000;83:787-8.
86. Heit JA, Petterson TM, Owen WG, Burke JP, de Andrade M, Melton J. Thrombomodulin gene polymorphisms or haplotypes as potential risk factors for venous thromboembolism: A population-based case-control study. J Thromb Haemost 2004;3:710-7.
87. Sugiyama S, Hirota H, Kimura R, Kokubo Y, Kawasaki T, Suehisa E, et al. Haplotype of thrombomodulin gene associated with plasma thrombomodulin level and deep vein thrombosis in the Japanese population. Thromb Res 2007;119: 35-43.
88. Medina P, Navarro S, Estellés A, Espana F. Polymorphisms in the endothelial protein C receptor gene and thrombophilia. Thromb Haemost 2007;98:564-9.
89. Poort SR, Vos HL, Rosendaal FR, Bertina RM. The endothelial protein C receptor (EPCR) 23 bp insert mutation and the risk of venous thrombosis. Thromb Haemost 2002;88:160-2.
90. Medina P, Navarro S, Estellés A, Vayà A, Woodhams B, Mira Y, et al. Contribution of polymorphisms in the endothelial protein C receptor gene to soluble endothelial protein C receptor and circulating activated protein C levels, and thrombotic risk. Thromb Haemost 2004;91:905-11.
91. van Tilburg NH, Rosendaal FR, Bertina RM. Thrombin activatable fibrinolysis inhibitor and the risk for deep vein thrombosis. Blood 2000;95:2855-9.
92. Boffa MB, Reid ST, Joo E, Nesheim ME, Koschinsky ML. Characterization of the gene encoding human TAFI (thrombinactivatable fibrinolysis inhibitor; plasma carboxypeptidase B). Biochemistry 1999;38:6547-58.
93. Franco RF, Fagundes MG, Meijers JC, Reitsma PH, Lourenço D, Morelli V, et al. Identification of polymorphisms in the 5'- untranslated region of the TAFI gene: Relationship with plasma TAFI levels and risk of venous thrombosis. Haematologica 2001;86:510-7.
94. Martini CH, Brandts A, de Bruijne EL, van Hylckama Vlieg A, Leebeek FW, Lisman T, et al. The effect of genetic variants in the thrombin activatable fibrinolysis inhibitor (TAFI) gene on TAFI-antigen levels, clot lysis time and the risk of venous thrombosis. Br J Haematol 2006;134:92-4.
95. Pabinger I, Ay C. Biomarkers and venous thromboembolism. Arterioscler Thromb Vasc Biol 2009;29:332-6.
96. Ay C, Simanek R, Vormittag R, Dunkler D, Alguel G, Koder S, et al. High plasma levels of soluble P-selectin are predictive of venous thromboembolism in cancer patients: Results from the Vienna Cancer and Thrombosis Study (CATS). Blood 2008;112:2703-8.
97. Ay C, Jungbauer LV, Sailer T, et al. High concentrations of soluble P-selectin are associated with risk of venous throm boembolism and the P-selectin Thr715 variant. Clin Chem 2007;53:1235-43.
98. Bezemer ID, Bare LA, Doggen CJ, Arellano AR, Tong C, Rowland CM, et al. Gene variants associated with deep vein thrombosis. J Am Med Assoc 2008;299:1306-14.
99. Bezemer ID, Arellano AR, Tong CH, Rowland CM, Ireland HA, Bauer KA, et al. F9 Malmö, factor IX and deep vein thrombosis. Haematologica 2009;94:693-9.
100. van Minkelen R, de Visser MC, Houwing-Duistermaat JJ, Vos HL, Bertina RM, Rosendaal FR. Haplotypes of IL1B, IL1RN, IL1R1, and IL1R2 and the risk of venous thrombosis. Arterioscler Thromb Vasc Biol 2007;27:1486-91.
101. Reiner AP, Lange LA, Smith NL, Zakai NA, Cushman M, Folsom AR. Common hemostasis and inflammation gene variants and venous thrombosis in older adults from the Cardivascular Health Study. J Thromb Haemost 2009;7:1499-1505.